Product launch readiness

If you are currently in clinical development or looking for solutions to improve your financial or supply chain architecture, please join us to discuss requirements, timelines, and key personnel to be considered to ensure overall compliance and long-term profitability.

In April 2021, Zynlonta™ was approved in the US and in December 2022, the product received a conditional marketing authorization valid throughout the EU. This one-hour talk will take you through the ADC Therapeutics’ journey to prepare for the successful launch of Zynlonta™ in Europe, and how cross-functional expertise, coordinated teamwork, selection of the right partners and careful planning were key in this process. Based on this experience, ADC Therapeutics and its partners, Allegra, Supply Chain Operations, Veristat, and PrimeTax, will provide insights on milestones and challenges to be considered for the launch of a life sciences product and how this also applies to other situations such as the optimization of your commercial organization.